9999999997-15-000249.txt : 20150121 9999999997-15-000249.hdr.sgml : 20150121 20150121093127 ACCESSION NUMBER: 9999999997-15-000249 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20150121 DATE AS OF CHANGE: 20150121 20150121 20150121 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TG THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001001316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 363898269 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1934 Act SEC FILE NUMBER: 001-32639 FILM NUMBER: 15537570 BUSINESS ADDRESS: STREET 1: 787 SEVENTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: (212) 554-4484 MAIL ADDRESS: STREET 1: 787 SEVENTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10019 FORMER COMPANY: FORMER CONFORMED NAME: MANHATTAN PHARMACEUTICALS INC DATE OF NAME CHANGE: 20030310 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC TECHNOLOGY VENTURES INC DATE OF NAME CHANGE: 20000330 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19960703 CT ORDER 1 filename1.pdf begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0Q(#`@;V)J#3P\+TQI;F5AF4@-30O5'EP92]84F5F+U=;,2`R(#%=/CYS=')E86T-"FC>8F)D$&!@ M8F#R`A(,4X`$XPT@P1(.)-C.`(G/W0Q,C`P[0+(,C.C$?\;9?P`"#`#6M@?D M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@ M("`@#0HU,R`P(&]B:@T\/"]#(#8Y+T9I;'1E8F!@8&%@8(IF``(>6094P,@` MDN5H0!9C@6(&AAL,W`R<_WZQ+(`JE0V'T$QQR(KU7T!$&94!`@P`&3T&O@T* M96YD7!E+U!A9V4^/@UE;F1O8FH--#0@,"!O8FH-/#PO1FEL=&5R+T9L871E M1&5C;V1E+T9I/N7%>M.R.%;\0]Z9+B)A^6R; MK1L6:3ZKRG8RJ7X]7!B3D(TI(00E>"3K+-L5VY=WBV*7-^PV_\GNJEU6OB?; M;;;+.5G`0/M?YQ>3:KOZLB#[O*WS=KGAMU6]R[:T==\QLD+PFS;;%LOK#S-M]]8S**^>+E*2=?I%P73VU5\^]])=K8JRNH$^M&EV-?_U@NJU51KOE] M45Z73>'?9T7=M---5L,G][^!W88N\L]9[Z",X?/G'RW26=3/.?'RY"#SJMTT M#]8F[%\"1R.*(F8,C`:'BHD3!H%19E$>F)$$H(U M)';/<-_'].ND7SN[CP&B46`C4GT#R)YJII2@I\&GZ9MC`A[N!,+.=1N0U;]@ M")5DAO`PA4O=.?NHGB`20P_==U*-"#@@6/C3_(`T`>;-`9.00@_ M"8?RZ'1O4CR&F$>2)2^_H+%_*;_QOOP*>Y[\OJF\^HCR)N*T\.KDI/">J;GP M/_8?:ZX6@WRBHJ!-)J.K'.NS)=?/)N1PP-E-E=R[4^$]"./3W"FU)<,>< M'\:2Y$KI;5Z:^[A0<76<>C$AI>U5T:MC($#AO5+N'A_Z2P%>84_&BJNAGPK7 M"=Y#>5!QT>^TXF+U)+A2OA)BM? MZZT.CF@,+-3]^X;P.7L]6%:W3P$OU?O>A$JB7!_ M+LH"9R^='9NSZ4A%^_0$SI:)R#/_<#@IXS=!F/+!A_N[((QYA0\THV428/W1 MD-'C;X&,^.#'($QX?_1#T.QE@Y]QY7T0%C`HO9UVTD"/)#$Z<54)%-2W*TNM8B`^W%R*7C9&0!34::^0>34_9!` MN&>(QWT?8A?QD8.18&*TJF$:W0:E?J4W>K+]GPA.6KB'ES+E?7I`5(UP&T*5 MB*@\1XC\'"%@=]PBX\@X0\=2H'6(_R%3-$M.&=(?D#@C!!``)H-0\1*'&(?D MU*]4GO.KL'[%D5#II;"6+1@2`T."9\E8J-R'`6S-^0]`,$:S9R3VXW:"MF]H M?L!QCVFZ0+=G.W3N"M^S.YS6^'XFCGPJ19*>*7K9]A*917+/D?77]G%-EB"$5? MZJ(?2B5RS9;X#+2V!D7F^*'O&'57NFS;K"@RC(>SM@I.=L`F--XV:S MM%*H`=?V=F5=LT--!G1X->9S9SX[KMSWB(5,19H::P^.:BJ9:IHUI+$`*;;% MA$*A3P<I1F>Q6Z#PAFT@D*I>'0$ M?ZQ$VL[;$ZQ<*H_YKQ@4@F=IK3S2&(+*PKL+D!NH>`^)1V?PN4(5LG_SO26=I\)@T;RI!S.2UT592%4%Y>FY0&:7M)F':H(Y9C M3BPB)FI"+8@X%\GZ"89#LW.Y(`8@`33KC@B@))KHY9;%G&'E6-=/`#;!.'?X M+@S(E/Q:D&BRTL4`',08X3J(2E]V322R2FLJ6EV"^C4*TI955UQ-'1MKXT@U MO7^F@D3!N@VRAC!@%?%(F\K6J-O4VOCB4700T'3,^X&NJO3Z"CK-#[`@'I`. M8H",$2Q-U4<.JJ8?`QAIFM"T*>Z>D<.@.>,SC;NFO:`SM8FDDRS;T'AB&KK8 M0K/QE#V[8!)`^U9XW$U2Z_RJUR2@(5Q['F\.T_:%LJ1@Z4R:.[MG)GIKFY#, M756",0T=9@L.Y,W= M2]LHK;\$[9O('?U,R]/&"00DAK91^=U09^9^048OEZ?UEG9[Z68PIP++3&6S MEZH)H"F!36@\7S9-7]`.$+-L]F4=/"M[:V],YFC8YMXW56=YW-$'BBZ!,ZI\ M3[8C?J3>X=5Q#QCC%]VY#MA]K6C92RUP\=*U\?+#&#Y)Y'%0"TT8:,&%)*,3 M42;^9BFBK%.9!I78=2#./+.F$KVC:!W\#%'ZRLQ)HA!YT:9/FTX7/7D!$_>I M$V>7`%31"8`=++;.NM8$6B77V0PP[M3NK.ABPE]S";4)4`B(L+T%_5MX3RC] M[X7P"K($-^@^>F+OL5:E,YV?6NB MH5-'F#!*Y6KAW.NN4H=BMP.I7TY`]@BV_\8;4Q=E^V/P`5O]Q]E6UVQJ#R=- MTPJ]EB.#:>E%?M:5S+DBQ64"Y-W1O:EZ?PLP`,1QK_L-"F5N9'-TY!@9$1FEP'Z> M@8V!F0$,$I.+"QP#`GQ`[+S\O%0&#/#M&@,CB+ZL"S(+4QXO8$TN*"H!T@>` MV"@EM3@92'\!XLSRD@*@.&,"D"V2E`UF@]2)9(<$.0/9'4`V7TEJ!4B,P3F_ MH+(H,SVC1,'0TM)2P3$E/RE5(;BRN"0UMUC!,R\YOZ@@ORBQ)#4%J!9J!PCP MNQ`P8A0[CQ!#@.32HC(HDY')F($! M(,``2<8X+PT*96YDPJ>BE!2")2" M4&!*$2&4$B)2Y1$%?D*45)4((&I$134C:JH+(8!J@#F`AY^9D3'2W.!301RQ M@"^)"Z0DXGG!LB).R+HFKK"R>.(:609L#UDS"7@"B(`G1:1Y%U(5).!%[$?` MBS&1@!<3C@5>X7$P\(KHZ>+"W>#(GK9NTXRYF_9CSCC^WQ/K_#+=Y%<*;ML_ MYB_-`#5SQ_YUR&XWC:?#TK;M^VFUFI&WL(6&V=82HA$U"HU2(VE4&@MXMK6$ M4E@IK!16"BN%E<)*8:6P4D0IHA11BBA%E")*$:6(4F2AW+D-+=-NYW;YH"=; MGYZ>;YFG%RU^WQ-&;WL6V.8_/T-AS[X:H9 M?@T_=??X-[OU_+F&O=^CS]UCV^7=0P/#Y^ZOIVF>TU5@O?V1^]-T'IZ^/Q_& M=G@;#GG\1M]DWB] M5I7-JIC5:%8+LUJ:U616*[-:VS;>D67;"K:N8/L*MK!@&PNVLF`["[:T8%MC MVQJ_\\9L:VQ;8]L:V];8ML;_M/93@`$`^I&FMC.60B/SX*/'@Z>&UP;65T82!X;6QN#IX;7!T:STB061O8F4@6$U0($-O&%P+S$N,"\B/@H@("`@("`@("`\>&UP.DUO9&EF>41A M=&4^,C`Q-2TP,2TR,50P.3HR.3HT,2TP-3HP,#PO>&UP.DUO9&EF>41A=&4^ M"B`@("`@("`@(#QX;7`Z0W)E871E1&%T93XR,#$U+3`Q+3(Q5#`Y.C(Y.C0P M+3`U.C`P/"]X;7`Z0W)E871E1&%T93X*("`@("`@("`@/'AM<#I-971A9&%T M841A=&4^,C`Q-2TP,2TR,50P.3HR.3HT,2TP-3HP,#PO>&UP.DUE=&%D871A M1&%T93X*("`@("`@("`@/'AM<#I#&UP34TZ&UP M34TZ&UL;G,Z<&1F>#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P M9&9X+S$N,R\B/@H@("`@("`@("`\<&1F>#I3;W5R8V5-;V1I9FEE9#Y$.C(P M,34P,3(Q,30R.3(Q/"]P9&9X.E-O=7)C94UO9&EF:65D/@H@("`@("`@("`\ M<&1F>#I#;VUP86YY/E-E8W5R:71I97,@86YD($5X:&%N9V4@0V]M;6ES#I#;VUP86YY/@H@("`@("`@("`\<&1F>#I#;VUM96YT#I#;VUM96YT7!E+T]B:E-T;3X^NA-B/__I!8! M8;-I=CF=1:L_O-"H1+ M@DD43J*N;O;BGD'T#QU47!ZY2$X&GAWX\(-:O?TH64(6M,9 MJK?;/P$&`$*S3O4-"F5N9'-T